Summary
MAO-B activity was compared in healthy volunteers following oral treatment with clinically effective doses of the selective MAO-A inhibitors brofaromine (100 mg q.d. for 14 days), moclobemide (150 mg t.i.d. for 14 days) and clorgyline (5 mg t.i.d. for 10 days). Brofaromine and clorgyline did not alter platelet MAO activity. Following moclobemide treatment, MAO-B activity was reduced by 32% (p<0.05). It recovered during the 5 subsequent days after discontinuation of treatment. These results confirm earlier findings. The explanation for this finding may be that metabolities of moclobemide are active inhibitors of MAO-B.
This is a preview of subscription content, log in via an institution to check access.
References
Angst J, Stabl M (1992) Efficacy of moclobemide in different patient groups: a metaanalysis of studies. Psychopharmacology 106: S 109-S 113
Da Prada M, Kettler R, Keller HH, Bonetti EP (1986) Moclobemide, a new antidepressant inhibiting platelet monamine oxidase type-B (P/MAO-B) activity in man. Acta Pharmacol Toxicol 59 [Suppl V]: 108
Da Prada M, Kettler R, Keller HH, Burkard WP, Muggli-Maniglio D, Haefely W (1989) Neurochemical profile of moclobemide, a short-acting and reversible inhibitor of monamine oxidase type A. J Pharmacol Exp Ther 248: 400–414
Dollery CH, Murphy DL (1977) Substrate and inhibitor related characteristics of human platelet monoamine oxidase. Biochem Pharmacol 26: 853–858
Feiner AE, Waldmeier PC (1979) Cumulative effects of irreversible MAO inhibitors in vivo. Biochem Pharmacol 28: 995–1002
Möller HJ, Wendt G, Waldmeier P (1991) Brofaromine — a selective reversible, and shortacting MAO-A inhibitor: review of the pharmacological and clinical findings. Pharmacopsychiatry 24: 50–54
Murphy DL, Wright C, Buchsbaum M, Nichols A, Costa JL, Wyatt RJ (1976) Platelet and plasma amine oxidase activity in 680 normals: sex and age differences and stability over time. Biochem Med 16: 254–265
Nissinen E (1984) Determination of monoamine oxidase B activity by high-performance liquid chromatography. J Chromatogr 309: 156–159
Pickar D, Cohen RM, Jimerson DC, Lake CR, Murphy DL (1981) Tyramine infusions and selective monoamine oxidase inhibitor treatment. II. Interrelationship among pressor sensitivity changes, platelet MAO inhibition, and plasma MHPG reduction. Psychopharmacology 74: 8–12
Stefanis CN, Alevizos B, Markianos M, Hatzimanolis J (1988) Effect of moclobemide on clinical and neurochemical variables in depressed patients. J Neural Transm 26 [Suppl]: 97–104
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Gleiter, C.H., Nilsson, E., Mühlbauer, B. et al. Effect of the selective MAO-A inhibitors brofaromine, clorgyline and moclobemide on human platelet MAO-B activity. J. Neural Transmission 89, 129–133 (1992). https://doi.org/10.1007/BF01245359
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01245359